A carregar...
DD-02 PHARMACODYNAMIC BIOMARKER ASSESSMENTS IN A PHASE I/II TRIAL OF THE HYPOXIA-ACTIVATED PRODRUG TH-302 AND BEVACIZUMAB IN BEVACIZUMAB-REFRACTORY RECURRENT GLIOBLASTOMA
BACKGROUND: Glioblastoma (GBM) remains an incurable malignancy with rapid progression and poor survival. GBM exhibits a hypoxic nature, and treatment with bevacizumab (BEV) may increase intratumoral hypoxia. TH-302 is an investigational prodrug that selectively releases the DNA cross-linker (Br-IPM)...
Na minha lista:
Publicado no: | Neuro Oncol |
---|---|
Main Authors: | , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Oxford University Press
2014
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4218032/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou246.2 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|